Newsroom

Press Releases

Articles & Media

Reviva Pharmaceuticals on the Empowered Patient Podcast

February 6, 2024 | Podcast interview on Empowered Patient Radio with Karen Jagoda featuring Reviva Pharmaceuticals CEO Laxminarayan Bhat titled Next-Generation Schizophrenia Therapy New Chemical Entity for Acute Condition and Maintenance.

Reviva Pharmaceuticals on on RedChip TV

September 23, 2023 | RedChip Money Report video interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals.

Topline Data for Reviva's (RVPH) Phase III Study in Schizophrenia

September 19, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO shares expected timing for topline readout for brilaroxazine in schizophrenia.

Reviva: Brilaroxazine's Pharmaceutical Profile

September 19, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses brilaroxazine’s profile including drug-drug interaction performance and the role of inflammation in schizophrenia.

What to Expect from Reviva over the Remainder of 2023

September 19, 2023 | Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO outlines the company’s capital raising plans and planned uses for these funds

Fireside Chat with Reviva's CEO on Brilaroxazine and Antipsychotics

September 19, 2023 | Fireside Chat on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO expands on broader themes in CNS disorders.

Reviva: A Beacon of Hope for Those Suffering with Mental Illnesses.

August 29, 2023 | Reviva’s lead drug Brilaroxazine is expecting efficacy results for schizophrenia this year 2023.

KOL Webinar Video Replay: Brilaroxazine: a serotonin/dopamine modulator in late-stage development for Schizophrenia

May 2, 2023  | KOL webinar video replay featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals, and Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research).

KOL Webinar Slide Presentation: Brilaroxazine: a serotonin/dopamine modulator in late-stage development for Schizophrenia

May 2, 2023  | KOL webinar slide presentation featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals, and Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research).

Reviva: Nasdaq Amplify Issuer Spotlight

April 27, 2023  | Reviva was the Nasdaq Amplify Issuer Spotlight in the April 2023 edition of the Nasdaq Amplify Newsletter. Laxminarayan Bhat, CEO Reviva Pharmaceuticals, discusses Reviva’s pipeline and commitment to developing better, safer, and more effective treatment options.

Reviva: Phase 3 Trial in Schizophrenia Now Underway

April 11, 2023  | Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals discussing the Company’s Phase 3 trial for schizophrenia and much more.

Reviva Webcast at the 35th Annual Roth Conference

March 13, 2023  |  Laxminarayan Bhat, CEO of Reviva Pharmaceuticals, presented at the 35th Annual Roth Conference.

Reviva: Next Generation Blockbuster

March 10, 2023  |  Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s potential to safely improve quality of life for schizophrenia patients.

Reviva's Brilaroxazine Addresses Antipsychotics' Biggest Hurdles

March 10, 2023  |  Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s favorable efficacy profile along with how it addresses the Positive and Negative Syndrome Scale (PANSS).

Reviva's Clinical & Regulatory Timelines

March 10, 2023  |  Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses the company’s timelines over the next several quarters with respect to topline data readouts, FDA interaction and when we should see the second Phase III trial for Brilaroxazine.

Reviva: More Than Schizophrenia

March 10, 2023  |  Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO shares the future of the company in other indications including Bipolar Disorder, Major Depressive Disorder, ADHD, Pulmonary Arterial Hypertension and Idiopathic Pulmonary Fibrosis.

Fireside Chat: Reviva's RP1208 & Thoughts on Peers

March 10, 2023  |  Video Interview on Unboxing Biotech with John Vandermosten of Zacks Research. Reviva Pharmaceuticals CEO discusses Brilaroxazine’s favorable efficacy profile along with how it addresses the Positive and Negative Syndrome Scale (PANSS).

Reviva: Novel Therapies for Central Nervous System, Respiratory, and Metabolic Diseases

January 25, 2023  |  Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals.

Reviva: The Potential Future Standard of Care for Schizophrenia

October 15, 2022  |  Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals.

New Schizophrenia Drug Shows Promise of Greater Success with Fewer Side Effects

May 5, 2022 | RealClear Health article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals.

RVPH KOL Image

Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

May 3, 2022  |  KOL Webinar featuring Leslie Citrome, MD (New York Medical College), Larry Ereshefsky, PharmD (Apex Innovative Sciences), and Laxminarayan Bhat, CEO (Reviva Pharmaceuticals).

Unboxing Biotech Video Series

March 9, 2022  |  A 4-part video series with John Vandermosten of Zacks Research featuring Reviva Pharmaceuticals CEO Laxminarayan Bhat.

Engineered neuroreceptor-specificity set to deliver next-generation schizophrenia therapeutics

June 2021 | Nature Research article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals.

This page contains links to other third party sites. Clicking on a third party link will cause you to leave our website. The third party sites are not controlled by Reviva and we are not responsible for the content. Please see our Privacy Policy for more information regarding third party links and sites.